181 related articles for article (PubMed ID: 26360803)
21. Cutaneous Skeletal Hypophosphatemia Syndrome in Association with a Mosaic
Park PG; Park E; Hyun HS; Kang HG; Ha IS; Cho TJ; Ko JM; Cheong HI
Ann Clin Lab Sci; 2018 Sep; 48(5):665-669. PubMed ID: 30373874
[TBL] [Abstract][Full Text] [Related]
22. Unusually long-term responses to vemurafenib in BRAF V600E mutated colon and thyroid cancers followed by the development of rare RAS activating mutations.
Ofir Dovrat T; Sokol E; Frampton G; Shachar E; Pelles S; Geva R; Wolf I
Cancer Biol Ther; 2018; 19(10):871-874. PubMed ID: 30036146
[TBL] [Abstract][Full Text] [Related]
23. BRAF V600E expression and distribution in desmoplastic infantile astrocytoma/ganglioglioma.
Koelsche C; Sahm F; Paulus W; Mittelbronn M; Giangaspero F; Antonelli M; Meyer J; Lasitschka F; von Deimling A; Reuss D
Neuropathol Appl Neurobiol; 2014 Apr; 40(3):337-44. PubMed ID: 23822828
[TBL] [Abstract][Full Text] [Related]
24. Postzygotic HRAS and KRAS mutations cause nevus sebaceous and Schimmelpenning syndrome.
Groesser L; Herschberger E; Ruetten A; Ruivenkamp C; Lopriore E; Zutt M; Langmann T; Singer S; Klingseisen L; Schneider-Brachert W; Toll A; Real FX; Landthaler M; Hafner C
Nat Genet; 2012 Jun; 44(7):783-7. PubMed ID: 22683711
[TBL] [Abstract][Full Text] [Related]
25. BRAF V600E mutations are frequent in dysembryoplastic neuroepithelial tumors and subependymal giant cell astrocytomas.
Lee D; Cho YH; Kang SY; Yoon N; Sung CO; Suh YL
J Surg Oncol; 2015 Mar; 111(3):359-64. PubMed ID: 25346165
[TBL] [Abstract][Full Text] [Related]
26. Is Schimmelpenning Syndrome Associated with Intracranial Tumors? A Case Report.
Chiang MC; McDowell MM; Weaver K; Broniscer A; Greene S
Pediatr Neurosurg; 2019; 54(3):201-206. PubMed ID: 30879010
[TBL] [Abstract][Full Text] [Related]
27. Vemurafenib.
Garbe C; Abusaif S; Eigentler TK
Recent Results Cancer Res; 2014; 201():215-25. PubMed ID: 24756795
[TBL] [Abstract][Full Text] [Related]
28. BRAF V600E-mutated central nervous system tumor with divergent morphological feature - Anaplastic pleomorphic xanthoastrocytoma-like and astroblastoma-like.
Purkait S; Bansal S; Malgulwar PB
Neuropathology; 2019 Feb; 39(1):64-67. PubMed ID: 30557911
[TBL] [Abstract][Full Text] [Related]
29. Vemurafenib in pediatric patients with BRAFV600E mutated high-grade gliomas.
Bautista F; Paci A; Minard-Colin V; Dufour C; Grill J; Lacroix L; Varlet P; Valteau-Couanet D; Geoerger B
Pediatr Blood Cancer; 2014 Jun; 61(6):1101-3. PubMed ID: 24375920
[TBL] [Abstract][Full Text] [Related]
30. Expansion of the phenotypic spectrum and description of molecular findings in a cohort of patients with oculocutaneous mosaic RASopathies.
Chacon-Camacho OF; Lopez-Moreno D; Morales-Sanchez MA; Hofmann E; Pacheco-Quito M; Wieland I; Cortes-Gonzalez V; Villanueva-Mendoza C; Zenker M; Zenteno JC
Mol Genet Genomic Med; 2019 May; 7(5):e625. PubMed ID: 30891959
[TBL] [Abstract][Full Text] [Related]
31. Treatment patterns and outcomes in BRAF V600E-mutant melanoma patients with brain metastases receiving vemurafenib in the real-world setting.
Gibney GT; Gauthier G; Ayas C; Galebach P; Wu EQ; Abhyankar S; Reyes C; Guérin A; Yim YM
Cancer Med; 2015 Aug; 4(8):1205-13. PubMed ID: 25991583
[TBL] [Abstract][Full Text] [Related]
32. Role of diffusion weighted imaging for differentiating cerebral pilocytic astrocytoma and ganglioglioma BRAF V600E-mutant from wild type.
Ramaglia A; Tortora D; Mankad K; Lequin M; Severino M; D'Arco F; Löbel U; Benenati M; de Leng WWJ; De Marco P; Milanaccio C; Rossi A; Morana G
Neuroradiology; 2020 Jan; 62(1):71-80. PubMed ID: 31667545
[TBL] [Abstract][Full Text] [Related]
33. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.
Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA
Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428
[TBL] [Abstract][Full Text] [Related]
34. BRAF VE1 immunoreactivity patterns in epithelioid glioblastomas positive for BRAF V600E mutation.
Kleinschmidt-DeMasters BK; Aisner DL; Foreman NK
Am J Surg Pathol; 2015 Apr; 39(4):528-40. PubMed ID: 25581727
[TBL] [Abstract][Full Text] [Related]
35. Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model.
Duquette M; Sadow PM; Husain A; Sims JN; Antonello ZA; Fischer AH; Song C; Castellanos-Rizaldos E; Makrigiorgos GM; Kurebayashi J; Nose V; Van Hummelen P; Bronson RT; Vinco M; Giordano TJ; Dias-Santagata D; Pandolfi PP; Nucera C
Oncotarget; 2015 Dec; 6(40):42445-67. PubMed ID: 26636651
[TBL] [Abstract][Full Text] [Related]
36. Combination Treatment with the BRAF
Jeong JH; Oh JM; Jeong SY; Lee SW; Lee J; Ahn BC
Thyroid; 2019 Apr; 29(4):540-548. PubMed ID: 30869573
[TBL] [Abstract][Full Text] [Related]
37. A case of an epithelioid glioblastoma with the BRAF V600E mutation colocalized with BRAF intact low-grade diffuse astrocytoma.
Kuroda J; Nobusawa S; Nakamura H; Yokoo H; Ueda R; Makino K; Yano S; Kuratsu J
Neuropathology; 2016 Apr; 36(2):181-6. PubMed ID: 26375727
[TBL] [Abstract][Full Text] [Related]
38. Clinical neuropathology practice news 2-2012: BRAF V600E testing.
Capper D; Berghoff AS; von Deimling A; Preusser M
Clin Neuropathol; 2012; 31(2):64-6. PubMed ID: 22385786
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of EZH2 expression, BRAF V600E mutation, and CDKN2A/B deletions in epithelioid glioblastoma and anaplastic pleomorphic xanthoastrocytoma.
Wang J; Liu Z; Cui Y; Liu Y; Fang J; Xu L; He Y; Du J; Su Y; Zou W; Xu Z; Li G
J Neurooncol; 2019 Aug; 144(1):137-146. PubMed ID: 31214915
[TBL] [Abstract][Full Text] [Related]
40. Concurrent TERT promoter and BRAF V600E mutation in epithelioid glioblastoma and concomitant low-grade astrocytoma.
Matsumura N; Nakajima N; Yamazaki T; Nagano T; Kagoshima K; Nobusawa S; Ikota H; Yokoo H
Neuropathology; 2017 Feb; 37(1):58-63. PubMed ID: 27302309
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
